Zyomyx Names Robert Monaghan New CEO
Monday June 9, 8:09 am ET
Company to Pursue Market-Driven Strategy for Protein Profiling Biochip System and Biochips for Pharmaceutical, Biotechnology and Academic Customers
HAYWARD, Calif., June 9 /PRNewswire/ -- Zyomyx, Inc., a leader in protein biochip technologies, today announced the appointment of Robert (Bob) Monaghan to the position of chief executive officer. Mr. Monaghan (age 56) will succeed Lawrence Cohen, Ph.D., who has served as the company's president and CEO since 2001. Dr. Cohen has been appointed Vice Chairman and will continue his fulltime involvement with Zyomyx.
In his role as CEO, Mr. Monaghan will be responsible for overseeing the ongoing development and commercialization of Zyomyx' Protein Profiling Biochip System and protein biochips for pharmaceutical, biotechnology and academic customers. Mr. Monaghan has also joined Zyomyx' Board of Directors.
"The opportunity to lead Zyomyx as it evolves from a company focused on technology and product development to an integrated commercial organization is an exciting one," said Mr. Monaghan. "The unparalleled performance and flexibility provided by the Zyomyx system and protein biochips in conducting rich, accurate multiplexed protein expression analysis has the potential to transform the discovery, pre-clinical and clinical phases of drug development as well as diagnostics. Based on customer feedback, Zyomyx will be focusing on the commercialization of products to facilitate therapeutic and diagnostic programs, with emphasis in inflammation, cardiovascular, and oncology, in line with the unique capabilities of our current protein biochip line and biochip products in our pipeline."
"My decision to transition from CEO has been greatly eased by the knowledge that Bob is well-qualified to advance Zyomyx to the next stage of its commercial cycle as a recognized developer and marketer of indispensable protein analysis technologies for therapeutic development and patient diagnosis," said Dr. Cohen. "Bob has an established industry track record in directing companies from product development stage through successful commercialization and beyond. Based on what we have accomplished to date and Bob's valuable experience, I am confident that Zyomyx will achieve even greater success and larger market opportunities. I look forward to our ongoing collaboration as he assumes leadership of the company."
Robert Monaghan brings twenty-five years of relevant product commercialization experience and industry leadership to Zyomyx. Most recently, he served as president of Sigma Diagnostics and its subsidiaries. At Sigma, Mr. Monaghan shepherded the company's growth, performance, improved customer relations, and strategic repositioning, resulting in the sale of the company in 2002. Prior to his tenure at Sigma, Mr. Monaghan was vice president, LOCI research development with Dade Behring, Inc. Mr. Monaghan also served as vice president, Sales, with Behring Diagnostics. In addition, Mr. Monaghan held varied positions of increasing responsibility in business development, sales and marketing with SYVA Company (a division of Syntex Pharmaceuticals), Ciba Corning Diagnostics, Health Charge Corporation, Amherst Associates, a hospital finance consulting group, and the American Hospital Supply Corporation. He received an MBA in Marketing from California State University, San Bernardino and a B.S. degree in Business Administration from Arizona State University.
"On behalf of the Board, I am pleased to welcome Bob Monaghan to Zyomyx. We are confident in Bob's capabilities to lead the company," said Michael Goldberg, Chairman of the Zyomyx Board. "In addition, we wish to express our sincere appreciation for Larry's leadership in steering the company from its earliest stages of development into the commercialization. Larry established a high standard for performance and innovation throughout the organization, and provided significant insight and vision into translating Zyomyx' breakthrough technology into highly relevant products for the life sciences industry."
A New Era of Market-driven Proteomic Applications
The Zyomyx Protein Profiling System and the company's line of biochips are particularly well suited for therapeutic and diagnostics discovery and development applications. In February of this year, Zyomyx launched the Protein Profiling Biochip System and the first of several protein biochips, the Human Cytokine Biochip. Until recently, the productivity of research was limited by tools that could examine a small fraction of the proteins present in a sample at one time. Zyomyx' multiplexed, high-throughput system lifts the constraints on protein analysis, allowing scientists to engage in more productive and cost-effective protein research. The Protein Profiling Biochip System and Human Cytokine Biochips enable researchers to profile the expression of 30 cytokines in human serum samples simultaneously. The applications for the technology extend throughout the drug discovery and development process, including validation of therapeutic targets and biomarkers, selection of drug candidates and evaluation of effects of drugs in pre-clinical and clinical studies. Customers already include the Harvard Partners Genome Center, GlaxoSmithKline and Aventis.
About Zyomyx
Zyomyx is an innovator in the application of biological, biochemical and material science technologies to protein analysis platforms. The company's initial product offering, the Zyomyx Protein Profiling Biochip System significantly advances the field of protein analysis by providing the first, ready-to-use, automated and validated multiplexed platform for protein profiling. Zyomyx is privately held company based in Hayward, California. For more information about Zyomyx, please visit the company's website at www.zyomyx.com. |
